GSK agrees to acquire Nuvalent for $10.6 bln, expects third-quarter close
( June 9, 2026, 12:31 GMT | Official Statement) -- MLex Summary: London-based GSK agreed to acquire Boston-based Nuvalent, a clinical-stage biopharmaceutical company focused on creating targeted oncology therapies, for $10.6 billion. The deal includes multi-product oncology assets with validated targets that aim to address efficacy and/or tolerability limitations of existing therapies. The deal includes two late-stage, ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors for non-small cell lung cancer (NSCLC) currently under US FDA review for 2026 approval. And it accelerates GSK's entry into lung cancer treatment, providing a platform for expansion with Ris-Rez, GSK's B7-H3 antibody-drug conjugate. Statement follows in full. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.